In dogs affected by XL-PRA, retinal cells progressively deteriorate over time, preventing the eyes from functioning normally.
XL-PRA is considered one of the more severe forms of Progressive Retinal Atrophy (PRA) because symptoms often appear at an early age and the disease tends to progress rapidly. The condition primarily affects male dogs because it is inherited through the X chromosome. Female dogs can be carriers without showing noticeable signs of the disease, although some may develop mild symptoms depending on genetic factors.
One of the earliest signs of XL-PRA is night blindness, also known as nyctalopia. Owners may notice that affected dogs become hesitant in dim lighting, struggle to navigate at night, or bump into objects in darker environments. As the disease progresses, daytime vision also becomes impaired. Over time, affected dogs may experience complete blindness. Some dogs may also develop secondary eye changes such as cataracts or an increased reflective appearance of the eyes.
Despite vision loss, many dogs adapt remarkably well to their surroundings by relying on their senses of smell and hearing. However, early diagnosis remains important for proper management, safety, and breeding decisions. Because the disease is progressive and irreversible, identifying affected or carrier dogs through genetic testing is essential for reducing the spread of the mutation within breeding populations.
XL-PRA is inherited in an X-linked recessive pattern. Male dogs possess one X chromosome and one Y chromosome, so inheriting a single copy of the mutation on the X chromosome is enough for them to develop the disease. Female dogs have two X chromosomes, meaning they usually need two copies of the mutation to become fully affected. Females with only one mutated copy are typically carriers and may pass the mutation to their offspring without showing severe symptoms themselves.
The XL-PRA genetic test determines whether a dog is genetically clear, a carrier, or affected by the mutation associated with the condition. Testing is usually performed using a simple cheek swab or blood sample. Laboratory analysis of the dog’s DNA can accurately identify the presence of the defective gene, even before clinical signs appear. This makes genetic screening a valuable tool for breeders, veterinarians, and dog owners.
Responsible breeding practices are critical in controlling XL-PRA. Breeding affected males or carrier females can increase the risk of producing puppies that may suffer from the disease. By testing breeding dogs before mating, breeders can make informed decisions that help reduce the occurrence of XL-PRA in future generations while maintaining genetic diversity within the breed.
Currently, there is no cure for X-linked Progressive Retinal Atrophy. Treatment focuses on supportive care and helping affected dogs maintain a safe and comfortable quality of life. Regular veterinary eye examinations, stable home environments, and avoiding sudden changes in surroundings can help blind or visually impaired dogs adapt more easily.
Testing for XL-PRA demonstrates a commitment to responsible dog breeding and long-term canine health. Early identification of carriers and affected dogs helps protect future generations and supports the welfare and wellbeing of the breed as a whole.
